Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir for Inflammation in HIV/CMV Coinfection
NCT04840199Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of letermovir in cytomegalovirus infection (CMV), sponsored by National Institute of Allergy and Infectious Diseases. Started Apr 2022; status: terminated.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT04840199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04840199.